Daily Coverage on Healthcare Stocks, Valeant Pharma, Knight Therapeutics, Acerus Pharma, and Nuvo Pharma

LONDON, UK / ACCESSWIRE / October 10, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the Drug Manufacturers industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: Valeant Pharmaceuticals International, Knight Therapeutics, Acerus Pharma, and Nuvo Pharma. Register for these free reports at:

http://protraderdaily.com/register/

At the close of the Canadian markets on Friday, October 06, 2017, the Toronto Exchange Composite index ended the trading session at 15,728.32, 0.30% lower from its previous closing price.

The Healthcare Index was also in the red, closing the day at 68.85, down 0.56%.

Pro-Trader Daily's complimentary research reports on the following stocks are now available: Valeant Pharmaceuticals International Inc. (TSX: VRX), Knight Therapeutics Inc. (TSX: GUD), Acerus Pharmaceuticals Corporation (TSX: ASP), and Nuvo Pharmaceuticals Inc. (TSX: NRI). Sign up now for your free membership and research reports at:

http://protraderdaily.com/register/

Valeant Pharmaceuticals International, Inc.

Laval, Canada headquartered Valeant Pharmaceuticals International Inc.'s stock edged 0.87% lower, to finish Friday's session at $18.13 with a total volume of 469,090 shares traded. Valeant Pharma's shares have gained 9.75% in the past one month. Shares of the Company, which operates as a pharmaceutical and medical device company worldwide, are trading above its 50-day and 200-day moving averages. Valeant Pharma's 200-day moving average of $17.38 is above its 50-day moving average of $17.35. See our research report on VRX.TO at:

http://protraderdaily.com/optin/?symbol=VRX

Knight Therapeutics Inc.

On Friday, shares in Montreal, Canada headquartered Knight Therapeutics Inc. recorded a trading volume of 30,840 shares. The stock ended the day 0.11% higher at $8.77. Knight Therapeutics' stock has advanced 1.27% in the previous one month. The Company's shares are trading above its 50-day moving average. The stock's 200-day moving average of $9.61 is above its 50-day moving average of $8.56. Shares of Knight Therapeutics, which engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally, are trading at a PE ratio of 61.76. The complementary research report on GUD.TO at:

http://protraderdaily.com/optin/?symbol=GUD

Acerus Pharmaceuticals Corp.

On Friday, shares in Mississauga, Canada headquartered Acerus Pharmaceuticals Corp. ended the session 7.41% lower at $0.13 with a total volume of 90,016 shares traded. Acerus Pharma's shares have gained 18.18% in the last one month and 8.33% in the previous three months. Shares of the Company, which focuses on developing, manufacturing, marketing, and distributing pharmaceutical products for men's urology and women's hormone replacement therapy, and female sexual dysfunction, are trading above its 50-day and 200-day moving averages. Furthermore, the stock's 200-day moving average of $0.12 is greater than its 50-day moving average of $0.11. Register for free and access the latest research report on ASP.TO at:

http://protraderdaily.com/optin/?symbol=ASP

Nuvo Pharmaceuticals Inc.

Mississauga, Canada headquartered Nuvo Pharmaceuticals Inc.'s stock closed the day 1.19% higher at $4.25. The stock recorded a trading volume of 5,407 shares. Nuvo Pharma's shares have advanced 1.43% in the last three months. The Company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $4.51 is greater than its 50-day moving average of $4.35. Shares of the Company, which produces and sells pharmaceutical products in the US, Canada, and Europe, are trading at a PE ratio of 9.84. Get free access to your research report on NRI.TO at:

http://protraderdaily.com/optin/?symbol=NRI

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily